New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
06:06 EDTOSUR, TMOOraSure and Thermo Fisher to launch substance abuse testing device
OraSure (OSUR) announced continued progress under its agreement with Thermo Fisher (TMO) to develop and supply homogenous fully-automated oral fluid drugs of abuse assays to be used with a new version of the company's Intercept oral fluid specimen collection device. The NIDA-5 panel of automated assays developed by Thermo Fisher and the new Intercept oral fluid specimen collection device are expected to launch in the domestic criminal justice and forensics markets in Q4. As a result of this progress, OraSure has issued its final purchase order for fully-automated assays previously developed under its now terminated collaboration with Roche Diagnostics. Under the Roche Diagnostics collaboration, which was terminated in November 2013, OraSure is entitled to receive $5.5M as a result of its submission of a final purchase order. Payment is expected to be received during Q3.
News For OSUR;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
07:22 EDTTMOAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 22, 2014
11:34 EDTTMOLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
06:13 EDTTMOThermo Fisher reports Q3 Life Sciences Solutions revenue $1.07B
Subscribe for More Information
06:12 EDTTMOThermo Fisher reports expanded adjusted margin by 250 basis points in Q3
Subscribe for More Information
06:02 EDTTMOThermo Fisher narrows FY14 adjusted EPS to $6.87-$6.95 from $6.85-$6.97
Subscribe for More Information
06:00 EDTTMOThermo Fisher reports Q3 adjusted EPS $1.71, consensus $1.69
Subscribe for More Information
October 21, 2014
15:35 EDTTMONotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use